TABLE 5.
In vitro susceptibility of CLV-resistant clones to other antiviral agents
| Clone | Avg IC50 (fold resistance) ± SDa |
||||
|---|---|---|---|---|---|
| CLV | LMV | ADV | TDF | ETV | |
| WT | 0.9 (1) | 3.3 (1) | 6.3 (1) | 2.5 (1) | 0.01 (1) |
| 40-3 | >100 (>111) | >100 (>30) | 2.5 ± 0.6 (0.4 ± 0.1) | 5.2 ± 0.8 (2.1 ± 0.4) | 0.7 ± 0.04 (69 ± 4.2) |
| 46-8 | >100 (>111) | >100 (>30) | 7.8 ± 0.4 (1.25 ± 0.1) | 6.6 ± 0.5 (2.7 ± 0.2) | 0.7 ± 0.1 (69 ± 12) |
| 48-3 | >100 (>111) | >100 (>30) | 8.5 ± 0.8 (1.4 ± 0.1) | 4.7 ± 0.8 (1.9 ± 0.4) | >5 (>500) |
| 50-2 | >100 (>111) | >100 (>30) | 3.5 ± 0.8 (0.6 ± 0.1) | 5.9 ± 0.4 (2.3 ± 0.1) | 0.7 ± 0.1 (70 ± 12) |
a
SDs were calculated on the basis of at least three independent experiments. Fold resistance = (mutant IC50)/(WT IC50).